Form4insider filings, from the source

SEC Form 4 · accession 0001209191-15-040618

ReShape Lifesciences Inc. · RSLS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
May 6, 2015
Accepted (ET)
May 8, 2015 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001371217

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———2,000D
Common Stockholding———11,800IFamily Trust

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Director Option (right to buy)F1$1.12May 6, 2015A25,000AMay 6, 2015May 6, 2025Common Stock25,00025,000D
Director Option (right to buy)F2$1.12May 6, 2015A25,000AJun 6, 2015May 6, 2025Common Stock25,00025,000D
Director Option (right to buy)F1$44.77holding———Apr 27, 2007Apr 27, 2017Common Stock4,5784,578D
Director Option (right to buy)F1$26.40holding———May 6, 2008May 6, 2018Common Stock3,3333,333D
Director Option (right to buy)F1$11.58holding———May 5, 2009May 5, 2019Common Stock1,6661,666D
Director Option (right to buy)F1$2.52holding———May 6, 2010May 6, 2020Common Stock1,6661,666D
Director Option (right to buy)F1$2.63holding———May 5, 2011May 5, 2021Common Stock10,00010,000D
Director Option (right to buy)F1$2.77holding———May 9, 2012May 9, 2022Common Stock10,00010,000D
Director Option (right to buy)F1$0.88holding———May 8, 2013May 8, 2023Common Stock10,00010,000D
Director Option (right to buy)F1$1.84holding———May 7, 2014May 7, 2024Common Stock25,00025,000D

Explanation of responses